Mara Goldstein

AbbVie Inc (NYSE: ABBV) has selected a second target under an existing collaboration with CytomX Therapeutics Inc (NASDAQ: CTMX) for probody technology. This development is “incrementally positive” for CytomX Therapeutics and validates its probody technology and commercial potential,...

NewLink Genetics Corp (NASDAQ: NLNK), a late-stage biopharmaceutical company that focuses on cancer treatments, said on Friday it will review its clinical program after Merck & Co., Inc. (NYSE: MRK) and Incyte Corporation (NASDAQ: INCY) said their clinical trial of the similar drug epacadostat...

Investors and analysts don’t seem to be in lockstep when it comes to NewLink Genetics Corp (NASDAQ: NLNK)’s potential. On Monday, the biotech firm secured Buy reiterations from Stifel Nicolaus and Cantor Fitzgerald, and last week, it earned upgrades to Buy from Jefferies and Baird...

The American Society of Hematology (ASH) held its annual December meeting in San Diego, where some of the biggest biotech companies announced clinical trial results, new drug updates and future initiatives. In separate reports, Cantor Fitzgerald analysts mentioned their takes on the announcements...

Cantor analyst Mara Goldstein likes Ignyta Inc (NASDAQ: RXDX) shares for the opportunity provided by Entrectinib, which has multiple indications. As a result, she is confident that the drug could generate a bigger market than expected. The brokerage reiterated its rating of Buy and kept $18.00 as...

Cantor analysts, Mara Goldstein and Monica Gorman, believe that there existed Biosimilar play with potential for interchangeability in respect of Oncobiologics Inc (NASDAQ: ONSIU) shares. As a result, the two analysts have initiated the stock with a Buy Rating and kept a price tag of $15.00....

Relypsa Inc (NASDAQ: RLYP) released the April sales data for Veltassa. Cantor Fitzgerald’s Mara Goldstein reiterated a Buy rating on the company, with a price target of $41. Developing Opportunity “Our view has been that the Veltassa launch would be the biggest risk to Relypsa shares,...

The filing of NDA for Abaloparatide-SC removes a key overhang on the shares of Radius Health Inc (NASDAQ: RDUS), according to Cantor Fitzgerald. Radius Health announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for abaloparatide–SC 80...

Cantor Fitzgerald's Mara Goldstein reiterated a Buy rating on Relypsa Inc (NASDAQ: RLYP), with a price target of $42. Mentioning that the "Veltassa prescription data released by RLYP looks good," Goldstein said that the numbers looked especially robust when compared to "...